TY  - JOUR
AU  - Perić, Aneta
AU  - Toskić-Radojičić, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Antunović, Mirjana
AU  - Bojić, Vedrana
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2049
AB  - Introduction and objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with anti-inflammatory, analgetic and antipyretic properties and are used in the treatment of acute mild to moderate pain, chronic pain and inflammatory conditions and fever. The aim of the study was to analyze the consumption of NSAIDs, purpose of use, length of therapy, adverse effects and patient's perception about efficacy and safety of the drugs. All patients, who had a NSAID prescribed, were included in the study. Method: The research was done in the Military Medical Academy, Belgrade, Serbia from June to December 2008. A questionnaire filled with the assistance of a pharmacist, contained questions about co morbidities, use and adverse effects of NSAIDs. All patients with at least one NSAID prespription (diclofenac, ibuprofen, flurbiprofen, naproxen, piroxicam, tenoxicam, meloxicam) were included in the study. The responses were statistically processed using the /-test. Results: 160 patients were included in the study. The majority of the patients (59.4%) used one NSAID in tablet form (48.8%). The most frequent used were diclofenac and ibuprofen. 51.9% suffered from rheumatic diseases for more than 5 years. Every other patient used both NSAIDs and gastroprotective drugs, most often ranitidine (58.1%). Conclusion: The results show that rheumatic diseases are often present in older patients and that treatment with NSAIDs lasts longer than five years. Mild gastric problems have been recorded as adverse effects of NSAIDs, most often nausea and pain in the stomach. This is probably due to the frequent use of diclofenac and ibuprofen, drugs with low or moderate risk for gastric toxicity as well as the concomitant use of H2-antagonists and proton pump inhibitors.
AB  - Uvod i cilj rada: Nesteroidni antiinflamatorni lekovi (NSAIL) ispoljavaju antiinflamatorno, analgetičko i antipiretičko dejstvo i primenjuju se kod akutnih bolova blagog do umerenog intenziteta, hroničnih bolnih i zapaljenskih stanja, te povišene telesne temperature. Cilj ove studije bio je da se analizira vanbolnička potrošnja NSAIL, način primene, dužina terapije i neželjene reakcije, kao i iskustva pacijenata u vezi sa efikasnošću i bezbednošću lekova. U studiju su uključeni svi pacijenti kojima je propisan NSAIL. Metode: Istraživanje je sprovedeno u Vojnomedicinskoj akademiji u Beogradu, u periodu od juna do decembra 2008. godine. Pacijenti su, uz pomoć farmaceuta, popunjavali upitnik koji se sastojao od pitanja vezanih za pridružena oboljenja, upotrebu i neželjene efekte NSAIL. U studiju su uključeni svi pacijenti kojima je na recept bio propisan neki od NSAIL (diklofenak, ibuprofen, flurbiprofen, naproksen, piroksikam, tenoksikam, meloksikam). Odgovori su statistički obrađeni primenom x2-testa. Rezultati: U studiji je učestvovalo 160 pacijenata. Većina pacijenata (59,4%) je koristila jedan NSAIL, 48,8% ispitanika je primenjivalo lek u obliku tablete. Diklofenak i ibuprofen su najčešće korišćeni lekovi. U ispitivanoj grupi pacijenata, 51,9% pacijenata je bolovalo od reumatične bolesti duže od 5 godina. Svaki drugi pacijent je istovremeno primenjivao NSAIL i gastroprotektivni lek, najčešće ranitidin (58,1%). Zaključak: Rezultati pokazuju da se NSAIL često primenjuju duže od pet godina, u lečenju reumatičnih bolesti koje su zastupljene kod starijih pacijenata. Najčešći neželjeni efekti NSAIL su blagi gastrointestinalni problemi, nauzeja i bol u stomaku. Ovo se objašnjava time što se najviše koriste diklofenak i ibuprofen, lekovi koji imaju slab ili umeren rizik za ispoljavanje gastričnih neželjenih efekata, ali i zbog istovremene primene NSAIL i H2-blokatora/inhibitora protonske pumpe.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study
T1  - Vanbolnička primena nesteroidnih anti-inflamatornih lekova u Srbiji - opservaciona studija
VL  - 63
IS  - 5
SP  - 431
EP  - 442
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2049
ER  - 

@article{
author = "Perić, Aneta and Toskić-Radojičić, Marija and Vezmar-Kovačević, Sandra and Miljković, Branislava and Antunović, Mirjana and Bojić, Vedrana",
year = "2013",
abstract = "Introduction and objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with anti-inflammatory, analgetic and antipyretic properties and are used in the treatment of acute mild to moderate pain, chronic pain and inflammatory conditions and fever. The aim of the study was to analyze the consumption of NSAIDs, purpose of use, length of therapy, adverse effects and patient's perception about efficacy and safety of the drugs. All patients, who had a NSAID prescribed, were included in the study. Method: The research was done in the Military Medical Academy, Belgrade, Serbia from June to December 2008. A questionnaire filled with the assistance of a pharmacist, contained questions about co morbidities, use and adverse effects of NSAIDs. All patients with at least one NSAID prespription (diclofenac, ibuprofen, flurbiprofen, naproxen, piroxicam, tenoxicam, meloxicam) were included in the study. The responses were statistically processed using the /-test. Results: 160 patients were included in the study. The majority of the patients (59.4%) used one NSAID in tablet form (48.8%). The most frequent used were diclofenac and ibuprofen. 51.9% suffered from rheumatic diseases for more than 5 years. Every other patient used both NSAIDs and gastroprotective drugs, most often ranitidine (58.1%). Conclusion: The results show that rheumatic diseases are often present in older patients and that treatment with NSAIDs lasts longer than five years. Mild gastric problems have been recorded as adverse effects of NSAIDs, most often nausea and pain in the stomach. This is probably due to the frequent use of diclofenac and ibuprofen, drugs with low or moderate risk for gastric toxicity as well as the concomitant use of H2-antagonists and proton pump inhibitors., Uvod i cilj rada: Nesteroidni antiinflamatorni lekovi (NSAIL) ispoljavaju antiinflamatorno, analgetičko i antipiretičko dejstvo i primenjuju se kod akutnih bolova blagog do umerenog intenziteta, hroničnih bolnih i zapaljenskih stanja, te povišene telesne temperature. Cilj ove studije bio je da se analizira vanbolnička potrošnja NSAIL, način primene, dužina terapije i neželjene reakcije, kao i iskustva pacijenata u vezi sa efikasnošću i bezbednošću lekova. U studiju su uključeni svi pacijenti kojima je propisan NSAIL. Metode: Istraživanje je sprovedeno u Vojnomedicinskoj akademiji u Beogradu, u periodu od juna do decembra 2008. godine. Pacijenti su, uz pomoć farmaceuta, popunjavali upitnik koji se sastojao od pitanja vezanih za pridružena oboljenja, upotrebu i neželjene efekte NSAIL. U studiju su uključeni svi pacijenti kojima je na recept bio propisan neki od NSAIL (diklofenak, ibuprofen, flurbiprofen, naproksen, piroksikam, tenoksikam, meloksikam). Odgovori su statistički obrađeni primenom x2-testa. Rezultati: U studiji je učestvovalo 160 pacijenata. Većina pacijenata (59,4%) je koristila jedan NSAIL, 48,8% ispitanika je primenjivalo lek u obliku tablete. Diklofenak i ibuprofen su najčešće korišćeni lekovi. U ispitivanoj grupi pacijenata, 51,9% pacijenata je bolovalo od reumatične bolesti duže od 5 godina. Svaki drugi pacijent je istovremeno primenjivao NSAIL i gastroprotektivni lek, najčešće ranitidin (58,1%). Zaključak: Rezultati pokazuju da se NSAIL često primenjuju duže od pet godina, u lečenju reumatičnih bolesti koje su zastupljene kod starijih pacijenata. Najčešći neželjeni efekti NSAIL su blagi gastrointestinalni problemi, nauzeja i bol u stomaku. Ovo se objašnjava time što se najviše koriste diklofenak i ibuprofen, lekovi koji imaju slab ili umeren rizik za ispoljavanje gastričnih neželjenih efekata, ali i zbog istovremene primene NSAIL i H2-blokatora/inhibitora protonske pumpe.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study, Vanbolnička primena nesteroidnih anti-inflamatornih lekova u Srbiji - opservaciona studija",
volume = "63",
number = "5",
pages = "431-442",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2049"
}

Perić, A., Toskić-Radojičić, M., Vezmar-Kovačević, S., Miljković, B., Antunović, M.,& Bojić, V.. (2013). Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 63(5), 431-442.
https://hdl.handle.net/21.15107/rcub_farfar_2049

Perić A, Toskić-Radojičić M, Vezmar-Kovačević S, Miljković B, Antunović M, Bojić V. Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study. in Arhiv za farmaciju. 2013;63(5):431-442.
https://hdl.handle.net/21.15107/rcub_farfar_2049 .

Perić, Aneta, Toskić-Radojičić, Marija, Vezmar-Kovačević, Sandra, Miljković, Branislava, Antunović, Mirjana, Bojić, Vedrana, "Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study" in Arhiv za farmaciju, 63, no. 5 (2013):431-442,
https://hdl.handle.net/21.15107/rcub_farfar_2049 .

TY  - JOUR
AU  - Perić, Aneta
AU  - Toskić-Radojičić, Marija
AU  - Dobrić, Silva
AU  - Damjanov, Nemanja
AU  - Miljković, Branislava
AU  - Antunović, Mirjana
AU  - Vezmar, Sandra
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1366
AB  - Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.
PB  - Wiley-Blackwell, Malden
T2  - Journal of Evaluation in Clinical Practice
T1  - Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?
VL  - 16
IS  - 6
SP  - 1090
EP  - 1095
DO  - 10.1111/j.1365-2753.2009.01258.x
ER  - 

@article{
author = "Perić, Aneta and Toskić-Radojičić, Marija and Dobrić, Silva and Damjanov, Nemanja and Miljković, Branislava and Antunović, Mirjana and Vezmar, Sandra",
year = "2010",
abstract = "Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.",
publisher = "Wiley-Blackwell, Malden",
journal = "Journal of Evaluation in Clinical Practice",
title = "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?",
volume = "16",
number = "6",
pages = "1090-1095",
doi = "10.1111/j.1365-2753.2009.01258.x"
}

Perić, A., Toskić-Radojičić, M., Dobrić, S., Damjanov, N., Miljković, B., Antunović, M.,& Vezmar, S.. (2010). Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice
Wiley-Blackwell, Malden., 16(6), 1090-1095.
https://doi.org/10.1111/j.1365-2753.2009.01258.x

Perić A, Toskić-Radojičić M, Dobrić S, Damjanov N, Miljković B, Antunović M, Vezmar S. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice. 2010;16(6):1090-1095.
doi:10.1111/j.1365-2753.2009.01258.x .

Perić, Aneta, Toskić-Radojičić, Marija, Dobrić, Silva, Damjanov, Nemanja, Miljković, Branislava, Antunović, Mirjana, Vezmar, Sandra, "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?" in Journal of Evaluation in Clinical Practice, 16, no. 6 (2010):1090-1095,
https://doi.org/10.1111/j.1365-2753.2009.01258.x . .